Sản phẩm tự nhiên từ biển đã được thương mại hóa trong ngành dược phẩm và mỹ phẩm: Mẹo để thành công
Tóm tắt
Môi trường biển chứa đựng một số lượng lớn các sinh vật vĩ mô và vi mô đã phát triển những khả năng trao đổi chất độc đáo nhằm bảo đảm sự sống còn của chúng trong các môi trường sống đa dạng và khắc nghiệt, dẫn đến sự sinh tổng hợp của nhiều loại hợp chất chuyển hóa thứ cấp với các hoạt động cụ thể. Một số trong những hợp chất này là sản phẩm thương mại có giá trị cao cho ngành công nghiệp dược phẩm và mỹ phẩm. Mục tiêu của bài review này là phác thảo các con đường khám phá và phát triển sản phẩm tự nhiên từ biển, với trọng tâm đặc biệt vào các hợp chất đã thành công trong việc đưa ra thị trường, và đặc biệt xem xét các phương pháp mà các công ty dược phẩm và mỹ phẩm đã áp dụng để tiếp thị những sản phẩm đó. Những thách thức chính gặp phải trong quá trình khám phá và phát triển các hợp chất sinh học từ biển đã được phân tích và nhóm lại thành ba loại: đa dạng sinh học (khả năng tiếp cận tài nguyên biển và sàng lọc hiệu quả), cung cấp và kỹ thuật (sản xuất bền vững các hợp chất sinh học và hiểu biết về cơ chế hoạt động) và thị trường (quy trình, chi phí, quan hệ đối tác và tiếp thị). Các mẹo để vượt qua những thách thức này được đưa ra nhằm cải thiện tỷ lệ thành công trong việc gia nhập thị trường cho các hợp chất sinh học từ biển đầy hứa hẹn trong các quy trình hiện tại, nhấn mạnh những gì có thể được học từ những câu chuyện thành công và không thành công có thể áp dụng cho các chương trình khám phá và phát triển sản phẩm tự nhiên từ biển mới và/hoặc đang diễn ra.
Từ khóa
Tài liệu tham khảo
Mann, J., Davidson, R.S., Hobbs, J.B., Banthorpe, D.V., and Harbourne, J.B. (1994). Natural Products, Their Chemistry and Biological Significance, Longman Scientific and Technical Longman Group. [1st ed.].
Dias, 2012, A historical overview of natural products in drug discovery, Metabolites, 2, 303, 10.3390/metabo2020303
Carter, 2011, Natural products and Pharma 2011: Strategic changes spur new opportunities, Nat. Prod. Rep., 28, 1783, 10.1039/c1np00033k
Newman, 2012, Natural products as sources of new drugs over the 30 years from 1981 to 2010, J. Nat. Prod., 75, 311, 10.1021/np200906s
Margulis, L., and Schwartz, K.V. (1998). Five Kingdoms—An Illustrated Guide to the Phyla of Life on Earth, W.H. Freeman & Company. [3rd ed.].
Gerwick, 2012, Lessons from the past and charting the future of marine natural products drug discovery and chemical biology, Chem. Biol., 19, 85, 10.1016/j.chembiol.2011.12.014
Leal, 2012, Trends in the discovery of new marine natural products from invertebrates over the last two decades—Where and what are we bioprospecting?, PLoS One, 7, e30580, 10.1371/journal.pone.0030580
Bhatnagar, 2010, Immense essence of excellence: Marine microbial bioactive compounds, Mar. Drugs, 8, 2673, 10.3390/md8102673
Waters, 2010, The expanding role of marine microbes in pharmaceutical development, Curr. Opin. Biotechnol., 21, 780, 10.1016/j.copbio.2010.09.013
Penesyan, 2010, Development of novel drugs from marine surface associated microorganisms, Mar. Drugs, 8, 438, 10.3390/md8030438
Pettit, 1982, Isolation and characterization of palystatins A–D, J. Nat. Prod., 45, 272, 10.1021/np50021a007
Sudek, 2007, Identification of the putative bryostatin polyketide synthase gene cluster from “Candidatus Endobugula sertula”, the uncultivated microbial symbiont of the marine bryozoan Bugula neritina, J. Nat. Prod., 70, 67, 10.1021/np060361d
Molinski, 2009, Drug development from marine natural products, Nat. Rev. Drug Discov., 8, 69, 10.1038/nrd2487
Schumacher, 2011, Gold from the sea: Marine compounds as inhibitors of the hallmarks of cancer, Biotechnol. Adv., 29, 531, 10.1016/j.biotechadv.2011.02.002
Mishra, 2011, Natural products: An evolving role in future drug discovery, Eur. J. Med. Chem., 46, 4769, 10.1016/j.ejmech.2011.07.057
Nelson, 1988, Cosmetics. Content and function, Int. J. Dermatol., 27, 665, 10.1111/j.1365-4362.1988.tb01258.x
Kim, S.-K. (2012). Marine Cosmeceuticals: Trends and Prospects, CRC Press, Taylor & Francis Group.
Thomas, 2013, Beneficial effects of marine algal compounds in cosmeceuticals, Mar. Drugs, 11, 146, 10.3390/md11010146
Raposo, 2013, Bioactivity and applications of sulphated polysaccharides from marine microalgae, Mar. Drugs, 11, 233, 10.3390/md11010233
Kim, 2008, Anti-wrinkle activity of ziyuglycoside I isolated from a Sanguisorba officinalis root extract and its application as a cosmeceutical ingredient, Biosci. Biotechnol. Biochem., 72, 303, 10.1271/bbb.70268
Imhoff, 2011, Bio-mining the microbial treasures of the ocean: New natural products, Biotechnol. Adv., 29, 468, 10.1016/j.biotechadv.2011.03.001
Mayer, 2009, Marine pharmacology in 2005–6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action, Biochim. Biophys. Acta, 1790, 283, 10.1016/j.bbagen.2009.03.011
Ortholand, 2004, Natural products and combinatorial chemistry: Back to the future, Curr. Opin. Chem. Biol., 8, 271, 10.1016/j.cbpa.2004.04.011
Beutler, 2009, Natural products as a foundation for drug discovery, Curr. Protoc. Pharmacol., 46, 9.11.1, 10.1002/0471141755.ph0911s46
Radjasa, 2011, Highlights of marine invertebrate-derived biosynthetic products: Their biomedical potential and possible production by microbial associants, Bioorg. Med. Chem., 19, 6658, 10.1016/j.bmc.2011.07.017
Glaser, 2009, A renaissance in marine pharmacology: From preclinical curiosity to clinical reality, Biochem. Pharmacol., 78, 440, 10.1016/j.bcp.2009.04.015
Koehn, 2005, The evolving role of natural products in drug discovery, Nat. Rev. Drug Discov., 4, 206, 10.1038/nrd1657
Reynolds, 2002, Choosing the best pulse sequences, acquisition parameters, postacquisition processing strategies, and probes for natural product structure elucidation by NMR spectroscopy, J. Nat. Prod., 65, 221, 10.1021/np010444o
Leeds, 2006, Recent developments in antibacterial drug discovery: Microbe-derived natural products—From collection to the clinic, Expert Opin. Investig. Drugs, 15, 211, 10.1517/13543784.15.3.211
Brady, 2007, Construction of soil environmental DNA cosmid libraries and screening for clones that produce biologically active small molecules, Nat. Protoc., 2, 1297, 10.1038/nprot.2007.195
Li, 2005, Metagenomics-based drug discovery and marine microbial diversity, Trends Biotechnol., 23, 539, 10.1016/j.tibtech.2005.08.006
Galm, 2007, Natural product drug discovery: The times have never been better, Chem. Biol., 14, 1098, 10.1016/j.chembiol.2007.10.004
Zhang, 2008, Beyond the hapmap genotypic data: Prospects of deep resequencing projects, Curr. Bioinform., 3, 178, 10.2174/157489308785909232
Piel, 2006, Combinatorial biosynthesis in symbiotic bacteria, Nat. Chem. Biol., 2, 661, 10.1038/nchembio1206-661
Mayer, 2013, Marine pharmacology and the marine pharmaceuticals pipeline, FASEB J., 27, 1167.7, 10.1096/fasebj.27.1_supplement.1167.7
Newman, 2004, Marine natural products and related compounds in clinical and advanced preclinical trials, J. Nat. Prod., 67, 1216, 10.1021/np040031y
Mayer, 2010, The odyssey of marine pharmaceuticals: A current pipeline perspective, Trends Pharmacol. Sci., 31, 255, 10.1016/j.tips.2010.02.005
BCC Research. Available online: http://www.bccresearch.com/pressroom/phm/global-market-marine-derived-drugs-reach-nearly-$8.6-billion-2016.
Freedonia Group. Available online: http://www.freedoniagroup.com/FreedoniaStudyIndex.aspx.
EurOcean. Available online: http://www.eurocean.org/np4/2502.html.
Rouhi, 1995, Supply Issues Complicate Trek of Chemicals from the Sea to Market, Chem. Eng. News, 73, 42, 10.1021/cen-v073n047.p042
Leal, 2012, Bioprospecting of marine invertebrates for new natural products—A chemical and zoogeographical perspective, Molecules, 17, 9842, 10.3390/molecules17089842
Pettit, 2011, Culturability and secondary metabolite diversity of extreme microbes: Expanding contribution of deep sea and deep-sea vent microbes to natural product discovery, Mar. Biotechnol., 13, 1, 10.1007/s10126-010-9294-y
Montaser, 2011, Marine natural products: A new wave of drugs?, Future Med. Chem., 3, 1475, 10.4155/fmc.11.118
Hill, R.T. Marine Natural Products Biotechnology. Available online: http://www.eolss.net/sample-chapters/c17/e6-58-08-05.pdf.
Cragg, 2012, The impact of the United Nations Convention on Biological Diversity on natural products research, Nat. Prod. Rep., 29, 1407, 10.1039/c2np20091k
Costello, 2006, European marine biodiversity inventory and taxonomic resources: State of the art and gaps in knowledge, Mar. Ecol. Prog. Ser., 316, 257, 10.3354/meps316257
Jianga, 2013, Is coarse taxonomy sufficient for detecting macroinvertebrate patterns in floodplain lakes?, Ecol. Indic., 27, 48, 10.1016/j.ecolind.2012.11.015
Hughes, 2011, Principles of early drug discovery, Br. J. Pharmacol., 162, 1239, 10.1111/j.1476-5381.2010.01127.x
Gribbon, 2005, High-throughput drug discovery: What can we exulect from HTS?, Drug Discov. Today, 10, 17, 10.1016/S1359-6446(04)03275-1
Kingston, 2011, Modern natural products drug discovery and its relevance to biodiversity conservation, J. Nat. Prod., 74, 496, 10.1021/np100550t
Parker, C.N., Ottl, J., Gabriel, D., and Zhang, J.H. (2010). Natural Product Chemistry for Drug Discovery, Royal Society of Chemistry.
Suyama, 2011, Survey of marine natural product structure revisions: A synergy of spectroscopy and chemical synthesis, Bioorg. Med. Chem., 19, 6675, 10.1016/j.bmc.2011.06.011
Maier, 2009, Structural revisions of natural products by total synthesis, Nat. Prod. Rep., 26, 1105, 10.1039/b809658a
Michel, 2013, New concepts, experimental approaches, and dereplication strategies for the discovery of novel phytoestrogens from natural sources, Planta Med., 79, 514, 10.1055/s-0032-1328300
AntiBase 2012, The Natural Compound Identifier. Available online: http://www.wiley-vch.de/stmdata/antibase.php.
MarinLit Database™, 2012, University of Canterbury, Christchurch, New Zealand. Available online: http://www.chem.canterbury.ac.nz/marinlit/marinlit.shtml.
Dictionary of Natural Products Online™, A Subset of the Chapman & Hall/CRC CHEMICAL Database™. Available online: http://dnp.chemnetbase.com/dictionary-search.do?method=view&id=6930629&si=.
Theron, 2007, NAPROC-13: A database for the dereplication of natural product mixtures in bioassay-guided protocols, Bioinformatics, 23, 3256, 10.1093/bioinformatics/btm516
Børresen, T., Boyen, C., Dobson, A., Höfle, M., Ianora, A., Jaspars, M., Kijjoa, A., Olafsen, J., Querellou, J., and Rigos, G. Marine Biotechnology: A New Vision and Strategy for Europe. Marine Board-ESF Position Paper 15. Available online: http://www.marine.ie/NR/rdonlyres/C076682C-2B32-437C-A781-B2EACBAA6B62/0/ESFMBmarine_biotechnology_paper15LR.pdf.
Meyer, C.A. The Global Marine Pharmaceuticals Pipeline. Available online: http://marinepharmacology.midwestern.edu/.
Schuster, 2005, Why drugs fail—A study on side effects in new chemical entities, Curr. Pharm. Des., 11, 3545, 10.2174/138161205774414510
Lichtman, 2013, A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7 + 3, Blood Cells Mol. Dis., 50, 119, 10.1016/j.bcmd.2012.10.005
Cimino, 1984, Antiviral agents from a gorgonian, eunicella-cavolini, Experientia, 40, 339, 10.1007/BF01952539
Chhikara, 2010, Development of cytarabine prodrugs and delivery systems for leukemia treatment, Expert Opin. Drug Deliv., 7, 1399, 10.1517/17425247.2010.527330
Kripp, 2008, Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine, Int. J. Nanomed., 3, 397
National Cancer Institute, Clinical Trials (PDQ®). Available online: http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=6532271.
Clavis Pharma Announces Negative Outcome of Phase III CLAVELA Trial with Elacytarabine in Patients with Acute Myeloid Leukaemia. Available online: http://aqualis.no/home.
Shen, 2009, Design and synthesis of vidarabine prodrugs as antiviral agents, Bioorg. Med. Chem. Lett., 19, 792, 10.1016/j.bmcl.2008.12.031
Lloyd-Evans, L.P.M. A Study into the Prospects for Marine Biotechnology Development in the United Kingdom. Foresight Marine Panel, Marine Biotechnology Group 2005. Available online: http://www.vliz.be/imisdocs/publications/238815.pdf.
Mcintosh, 1982, Isolation and structure of a peptide toxin from the marine snail conus-magus, Arch. Biochem. Biophys., 218, 329, 10.1016/0003-9861(82)90351-4
Oliveira, B.M. (2000). Drugs from the Sea, Karger.
Bauer, 2013, Industrial natural product chemistry for drug discovery and development, Nat. Prod. Rep., 31, 35, 10.1039/C3NP70058E
Schmidtko, 2010, Ziconotide for treatment of severe chronic pain, Lancet, 375, 1569, 10.1016/S0140-6736(10)60354-6
(2010). Elan 2010 Annual Report, Elan Corporation.
Olivera, 2006, Conus peptides: Biodiversity-based discovery and exogenomics, J. Biol. Chem., 281, 31173
Vemomics for Health. Available online: http://www.venomics.eu/.
Glueck, 2012, Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dL despite conventional triglyceride lowering therapy, Lipids Health Dis., 11, 143, 10.1186/1476-511X-11-143
Rupp, 2009, OmacorA® (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia, Adv. Ther., 26, 675, 10.1007/s12325-009-0045-2
Koski, 2008, Omega-3-acid ethyl esters (lovaza) for severe hypertriglyceridemia, Pharm. Ter., 33, 271
Galmarini, 2010, A review of trabectedin (ET-743): A unique mechanism of action, Mol. Cancer Ther., 9, 2157, 10.1158/1535-7163.MCT-10-0263
Monk, 2012, Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer, Curr. Pharm. Des., 18, 3754, 10.2174/138161212802002814
Cuevas, 2009, Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem, Nat. Prod. Rep., 26, 322, 10.1039/b808331m
PharmaMar Annual report 2011. Available online: http://www.pharmamar.com/pdf/EN_memoria2012.pdf.
Aicher, 1992, Total synthesis of halichondrin-B and norhalichondrin-B, J. Am. Chem. Soc., 114, 3162, 10.1021/ja00034a086
Towle, 2001, In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B, Cancer Res., 61, 1013
NCI Development Therapeutics Program, Success storY: Halichondrin B (NSC 609395) E7389 (NSC 707389). Available online: http://dtp.nci.nih.gov/timeline/flash/success_stories/S4_halichondrinB.htm.
Pettit, 1987, Antineoplastic agents 136. The isolation and structure of a remarkable marine animal antineoplastic constituent—Dolastatin 10, J. Am. Chem. Soc., 109, 6883, 10.1021/ja00256a070
Eccles, 2010, Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: A randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold, Respir. Res., 11, 108, 10.1186/1465-9921-11-108
Euromonitor. Available online: http://www.euromonitor.com/skin-care.
Chi, 2005, Exopolysaccharides from marine bacteria, J. Ocean Univ. China, 4, 67, 10.1007/s11802-005-0026-2
Nichols, 2005, Bacterial exopolysaccharides from extreme marine environments with special consideration of the southern ocean, sea ice, and deep-sea hydrothermal vents: A review, Mar. Biotechnol., 7, 253, 10.1007/s10126-004-5118-2
Vincent, 1994, Production and characterization of an exopolysaccharide excreted by a deep-sea hydrothermal vent bacterium isolated from the polychaete annelid alvinella pompejana, Appl. Environ. Microbiol., 60, 4134, 10.1128/aem.60.11.4134-4141.1994
Raguenes, 1996, Description of a new polymer-secreting bacterium from a deep-sea hydrothermal vent, Alteromonas macleodii subsp. fijiensis, and preliminary characterization of the polymer, Appl. Environ. Microbiol., 62, 67, 10.1128/aem.62.1.67-73.1996
Raguenes, 1997, Vibrio diabolicus sp. nov., a new polysaccharide-secreting organism isolated from a deep-sea hydrothermal vent polychaete annelid, Alvinella pompejana, Int. J. Syst. Bacteriol., 47, 989, 10.1099/00207713-47-4-989
Raguenes, 1997, Alteromonas infernus sp. nov., a new polysaccharide-producing bacterium isolated from a deep-sea hydrothermal vent, J. Appl. Microbiol., 82, 422, 10.1046/j.1365-2672.1997.00125.x
Rougeaux, 1999, Structural determination of the exopolysaccharide of Pseudoalteromonas strain HYD 721 isolated from a deep-sea hydrothermal vent, Carbohydr. Res., 315, 273, 10.1016/S0008-6215(99)00019-1
Raguenes, 2002, A novel polymer produced by a bacterium isolated from a deep-sea hydrothermal vent polychaete annelid, J. Appl. Microbiol., 93, 310, 10.1046/j.1365-2672.2002.01689.x
Weiner, 1995, Structure, function and immunochemistry of bacterial exopolysaccharides, J. Ind. Microbiol., 15, 339, 10.1007/BF01569989
Desbruyeres, 1980, Alvinella pompejana gen. sp. nov., aberrant Ampharetidae from East Pacific Rise hydrothermal vents, Oceanol. Acta, 3, 326
Ropartz, 2012, Structural data on a bacterial exopolysaccharide produced by a deep-sea Alteromonas macleodii strain, Carbohydr. Polym., 90, 49, 10.1016/j.carbpol.2012.04.059
Thibodeau, 2006, The applications and functions of new exopolysaccharide “Deepsane” from the deepest oceans, Fragr. J., 34, 61
Potts, 1992, Phospholipase A2 inhibitors from marine organisms, J. Nat. Prod., 55, 1701, 10.1021/np50090a001
Day, 2013, Cyclodextrin formulation of the marine natural product pseudopterosin A uncovers optimal pharmacodynamics in proliferation studies of human umbilical vein endothelial cells, Mar. Drugs, 11, 3258, 10.3390/md11093258
Rouhi, 2003, Betting on natural products for cures, Chem. Eng. News, 81, 93, 10.1021/cen-v081n041.p093
Lipotec. Available online: http://www.lipotec.com.
Gottschalk, A. (1972). Glycoproteins: Their Composition, Structure and Function, Elsevier Publishing Company.
Martins, 2013, Photoprotective bioactivity present in a unique marine bacteria collection from Portuguese deep sea hydrothermal vents, Mar. Drugs, 11, 1506, 10.3390/md11051506
RefirMAR™ by BIOALVO. Available online: http://www.bioalvo.com/products/products-bioactive-ingredients/refirmar.
Satyanarayana, 2011, A review on microalgae, a versatile source for sustainable energy and materials, Int. J. Energy Res., 35, 291, 10.1002/er.1695
Stolz, 2005, Manufacturing microalgae for skin care, Cosmet. Toilet., 120, 99
CODIF Website. Available online: http://www.codif-recherche-et nature.com/en/s06_catalogue/s06p02_fiche.php?prod=56.
An Unlimite Mine of Innovation. Available online: http://greensea.fr/en/active-ingredients.
Patented Breakthrough Ingredient. Available online: http://www.algenist.com/why-algenist/patented-breakthrough-ingredient.
Frutarom. Available online: http://www.frutarom.com/FrutaromNew/index.asp.
Senaratne, 2006, Isolation and characterization of collagen from brown backed toadfish (Lagocephalus gloveri) skin, Bioresour. Technol., 97, 191, 10.1016/j.biortech.2005.02.024
Alan, 2000, Strategies for discovering drugs from previously unexplored natural products, Drug Discov. Today, 5, 294, 10.1016/S1359-6446(00)01511-7
Wagenaar, 2008, Pre-fractionated microbial samples—The second generation natural products library at Wyeth, Molecules, 13, 1406, 10.3390/molecules13061406
Cobb, 2014, DNA assembly techniques for next generation combinatorial biosynthesis of natural products, J. Ind. Microbiol. Biotechnol., 41, 469, 10.1007/s10295-013-1358-3
Pollier, 2011, Combinatorial biosynthesis in plants: A (p)review on its potential and future exploitation, Nat. Prod. Rep., 28, 1897, 10.1039/c1np00049g